At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 589 enrolled
Drug / intervention
Technosphere Insulin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multi-Center, Open-Label, Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety in Subjects With Type 1 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Basal and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow Up
In Brief
A Phase 3 clinical trial evaluating Technosphere Insulin and Active comparator for Diabetes, Type I. Completed, enrolled 589 participants across 129 sites in 10 countries.
Detailed Summary
To determine the safety and efficacy of inhaled insulin in the treatment of type 1 diabetes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Type I
CountriesArgentina, Brazil, Canada, Chile, Mexico, Poland, Russia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedMar 2006
Primary CompletionJul 2008
Study CompletionAug 2008
TodayJul 2026
First PostedMar 29, 2006
Enrollment StartFeb 1, 2006
Primary CompletionJul 1, 2008
Study CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 20.3 years ago
Interventions
Technosphere Insulindrug
Inhalation, 15U/30U
Active comparatordrug
sc injectable insulin